๐๐จ๐ซ๐ญ๐ก ๐๐ฆ๐๐ซ๐ข๐๐ ๐๐๐ฆ๐๐ญ๐จ ๐๐ง๐๐จ๐ฅ๐จ๐ ๐ฒ ๐๐๐ฌ๐ญ๐ข๐ง๐ ๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐, ๐๐ก๐๐ซ๐ & ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐๐ฉ๐จ๐ซ๐ญ (๐๐๐๐-๐๐๐๐)
๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐- https://lnkd.in/dFzurnhW
The North America hemato oncology testing market is set for strong growth over the forecast period. From an estimated USD 1,150 million in 2025, the market is forecasted to achieve USD 2,940 million by 2035. This performance is sustained by the rise in cancer cases, rapid innovation in NGS and PCR-based assays, and expanded adoption in both large cancer centers and community hospitals. Year-on-year revenue progression highlights significant investments by market leaders, continuous catchup from emerging companies, and a gradually widening consumer (patient) base benefiting from more accessible, affordable molecular diagnostics.
Key Drivers
Rising Incidence of Blood Cancers: The increasing prevalence of leukemia, lymphoma, and myeloma in North America is fueling demand for advanced hemato oncology testing. For example, Roche launched updated NGS panels for myeloid malignancies in June 2024, addressing early detection and personalized treatment needs.
Technological Advancements: Innovations such as automated PCR and NGS platforms are accelerating diagnostics. In July 2024, Illumina introduced a new liquid biopsy NGS solution for hematological cancers, enhancing sensitivity and workflow integration.
Key Trends
Shift Toward Comprehensive Genomic Profiling: Multi-omic and extensive panels are now preferred to enable precise cancer subtype differentiation. Thermo Fisher Scientific, in August 2024, expanded their Oncomine portfolio for blood cancers, reflecting this trend.
Integration of Artificial Intelligence (AI): AI-driven data interpretation tools are becoming central to labs. Adaptive Biotechnologies unveiled an AI-powered platform in July 2024 that improves clonality assessment in lymphoid malignancies.
Market Insights & Segmentation
Type (Assays and Kits, Services),
Application (Leukemia, Lymphoma, Myeloma, Others),
Distribution Channels (Direct Tenders, Retail Sales, Online Sales, Others),
Technology (PCR, NGS, IHC, FISH, Cytogenetics, Other Technologies),
Organization Size (Small, Medium, Large)
Key Market Companies
F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Agilent Technologies, Inc., Sysmex Corporation, Danaher Corporation, Invitae Corporation, PierianDx, Adaptive Biotechnologies, ArcherDX (A part of Invitae), Asuragen, Inc., NeoGenomics Laboratories, Inc.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ- https://lnkd.in/ddpidcX8
๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐- https://lnkd.in/dFzurnhW
The North America hemato oncology testing market is set for strong growth over the forecast period. From an estimated USD 1,150 million in 2025, the market is forecasted to achieve USD 2,940 million by 2035. This performance is sustained by the rise in cancer cases, rapid innovation in NGS and PCR-based assays, and expanded adoption in both large cancer centers and community hospitals. Year-on-year revenue progression highlights significant investments by market leaders, continuous catchup from emerging companies, and a gradually widening consumer (patient) base benefiting from more accessible, affordable molecular diagnostics.
Key Drivers
Rising Incidence of Blood Cancers: The increasing prevalence of leukemia, lymphoma, and myeloma in North America is fueling demand for advanced hemato oncology testing. For example, Roche launched updated NGS panels for myeloid malignancies in June 2024, addressing early detection and personalized treatment needs.
Technological Advancements: Innovations such as automated PCR and NGS platforms are accelerating diagnostics. In July 2024, Illumina introduced a new liquid biopsy NGS solution for hematological cancers, enhancing sensitivity and workflow integration.
Key Trends
Shift Toward Comprehensive Genomic Profiling: Multi-omic and extensive panels are now preferred to enable precise cancer subtype differentiation. Thermo Fisher Scientific, in August 2024, expanded their Oncomine portfolio for blood cancers, reflecting this trend.
Integration of Artificial Intelligence (AI): AI-driven data interpretation tools are becoming central to labs. Adaptive Biotechnologies unveiled an AI-powered platform in July 2024 that improves clonality assessment in lymphoid malignancies.
Market Insights & Segmentation
Type (Assays and Kits, Services),
Application (Leukemia, Lymphoma, Myeloma, Others),
Distribution Channels (Direct Tenders, Retail Sales, Online Sales, Others),
Technology (PCR, NGS, IHC, FISH, Cytogenetics, Other Technologies),
Organization Size (Small, Medium, Large)
Key Market Companies
F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Agilent Technologies, Inc., Sysmex Corporation, Danaher Corporation, Invitae Corporation, PierianDx, Adaptive Biotechnologies, ArcherDX (A part of Invitae), Asuragen, Inc., NeoGenomics Laboratories, Inc.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ- https://lnkd.in/ddpidcX8
257 Views
